S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:CGEM

Cullinan Management Stock Forecast, Price & News

$38.18
+0.35 (+0.93 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$35.95
Now: $38.18
$38.18
50-Day Range N/A
52-Week Range
$27.01
Now: $38.18
$43.00
Volume199,900 shs
Average Volume337,063 shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1883rd out of 1,926 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEM
CUSIPN/A
CIKN/A
Phone617-410-4650
Employees17

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.58 billion
Next Earnings DateN/A
OptionableNot Optionable
$38.18
+0.35 (+0.93 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGEM News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cullinan Management (NASDAQ:CGEM) Frequently Asked Questions

What stocks does MarketBeat like better than Cullinan Management?

Wall Street analysts have given Cullinan Management a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cullinan Management wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Cullinan Management's CEO?

1,448 employees have rated Cullinan Management CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Cullinan Management's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cullinan Management's key competitors?

Who are Cullinan Management's key executives?

Cullinan Management's management team includes the following people:
  • Mr. Owen P. Hughes Jr., CEO & Director (Age 46)
  • Dr. Patrick A. Baeuerle, Co-Founder & Acting Chief Scientific Officer of Biologics (Age 63)
  • Mr. Jeffrey Trigilio, Chief Financial Officer
  • Mr. Raymond T. Keane, Chief Legal Officer (Age 62)
  • Ms. Corinne Savill Ph.D., Acting Chief Bus. Officer (Age 62)
  • Mr. Leigh Zawel, Chief Scientific Officer of Small Molecules
  • Dr. Jennifer Michaelson Ph.D., Chief Devel. Officer of Biologics
  • Dr. Jon M. Wigginton, Chief Medical Officer (Age 59)
  • Ms. Kerry Whalen, Sr. Director of Preclinical & Early Devel.

When did Cullinan Management IPO?

(CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Cullinan Management's stock symbol?

Cullinan Management trades on the NASDAQ under the ticker symbol "CGEM."

When does the company's quiet period expire?

Cullinan Management's quiet period expires on Wednesday, February 17th. Cullinan Management had issued 11,900,000 shares in its IPO on January 8th. The total size of the offering was $249,900,000 based on an initial share price of $21.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Cullinan Management?

Shares of CGEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cullinan Management's stock price today?

One share of CGEM stock can currently be purchased for approximately $38.18.

How big of a company is Cullinan Management?

Cullinan Management has a market capitalization of $1.58 billion. Cullinan Management employs 17 workers across the globe.

What is Cullinan Management's official website?

The official website for Cullinan Management is www.cullinanoncology.com.

How can I contact Cullinan Management?

The company can be reached via phone at 617-410-4650.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.